Cargando…
Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration
Autores principales: | Nakamagoe, Kiyotaka, Tanaka, Mayuko, Igari, Kota |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024277/ https://www.ncbi.nlm.nih.gov/pubmed/36933100 http://dx.doi.org/10.1007/s10072-023-06754-4 |
Ejemplares similares
-
Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021) -
Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
por: Uzawa, Akiyuki, et al.
Publicado: (2022) -
Neuromyelitis optica pathogenesis and aquaporin 4
por: Graber, David J, et al.
Publicado: (2008) -
Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica
por: Paul, Friedemann, et al.
Publicado: (2007) -
Antibodies to aquaporin-1 are not present in neuromyelitis optica
por: Schanda, Kathrin, et al.
Publicado: (2015)